Board of Directors

• Thomas J. Schall, Ph.D., President, Chief Executive Officer and Director
• Rishi Gupta, J.D., Principal, OrbiMed Advisors
• Roger Lucas, Ph.D., Vice Chairman, Techne Corporation
• Geoffrey M. Parker, Senior Vice President and Chief Financial Officer,
  Anacor, Inc.
• Edward E. Penhoet, Ph.D., Director, Alta Partners

Thomas J. Schall, Ph.D.
President, Chief Executive Officer and Director
One of the earliest investigators in the field of chemokine biology, Dr. Schall is the founder of our company and has served as our President, Chief Executive Officer and Director since November 1996. From December 1993 to November 1996, Dr. Schall worked at the DNAX Research Institute, a division of Schering-Plough Corporation, a pharmaceutical company. Prior to his work at the DNAX Research Institute, he worked as a scientist with Genentech, Inc., a pharmaceutical company. Dr. Schall participated in some of the earliest discoveries of chemokine system function and activities. Dr. Schall cloned one of the first chemokines to be discovered, and provided some of the earliest data for the existence of the previously unknown family of molecules which later came to be called the chemokines. Dr. Schall's laboratories have been responsible for the discovery or co-discovery of almost one-third of all known chemokine receptors. Dr. Schall received his B.S. in biology from Northern Illinois University and his Ph.D. in cancer biology from Stanford University.

^ Return to Top

Rishi Gupta, J.D.
Principal, OrbiMed Advisors
Mr. Gupta has served a member of our board of directors since May 2011. Mr. Gupta has served as Private Equity Principal of OrbiMed Advisors LLC, a healthcare asset management company. From 1999 to 2000, Mr. Gupta served as corporate finance analyst in healthcare investment banking at Raymond James & Associates and from 2000 to 2001 served as Manager of Corporate Development at Veritas Medicine. Mr. Gupta received his A.B. degree magna cum laude in Biochemical Sciences from Harvard College and holds a J.D. from the Yale Law School. In addition to ChemoCentryx, Mr. Gupta serves on the board of directors of several companies.

^ Return to Top

Roger Lucas, Ph.D.
Vice Chairman, Techne Corporation
Dr. Lucas has served as a member of our board of directors since September 1997. Since 1995, Dr. Lucas has served as Vice Chairman and a member of the board of directors of Techne Corporation, a biotechnology company. From 1985 to 1995, Dr. Lucas served as the Chief Scientific Officer, Senior Executive Vice President and Secretary of Techne Corporation and the founder of its Biotechnology Division. Prior to this, Dr. Lucas was Vice President of Research at R&D Systems, now a subsidiary of Techne, where he worked for over ten years. Dr. Lucas received his B.S. in biology and chemistry from St. Mary's College, Minnesota and his Ph.D. in physiology and cell biology from Illinois Institute of Technology. Dr. Lucas also presently serves on the board of directors of a number of privately held companies.

^ Return to Top

Geoffrey M. Parker
Senior Vice President and Chief Financial Officer, Anacor, Inc.
Mr. Parker has served as a member of the ChemoCentryx Board of Directors since December 2009. Since September 2010, Mr. Parker has served as the Senior Vice President and Chief Financial Officer of Anacor Pharmaceuticals, Inc. after serving in a consulting capacity since December 2009. From July 2009 to July 2010, Mr. Parker served in a consulting capacity as the Chief Business Officer of InteKrin Therapeutics, Inc. a biotechnology company and previously served as Managing Director and Partner in the Investment Banking Division of Goldman, Sachs and Co. From 1997 to 2009, Mr. Parker directed Goldman Sach's West Region Healthcare Investment Banking practice. From 1995 to 1997, Mr. Parker was Vice President at Feibusch & Co., a venture capital firm in Larkspur, California. Mr. Parker received his A.B. in Engineering Sciences and Economics from Dartmouth College and his M.B.A. from Stanford University.

^ Return to Top

Edward E. Penhoet, Ph.D.
Director, Alta Partners
Dr. Penhoet has served as a member of our board of directors since December 2007. Since August 2000, Dr. Penhoet has served as a director of Alta Partners, a venture capital firm. Dr. Penhoet is currently a member of the President's Council of Advisors for Science and Technology (PCAST). Dr. Penhoet was a member of the Independent Citizens Oversight Committee of the California Institute of Regenerative Medicine where he served as the Vice Chairman from 2004 until 2008. From July 1998 to July 2002, Dr. Penhoet served as the Dean of the School of Public Health and as a Professor of Public Health and of Molecular and Cellular Biology at the University of California, Berkeley. Dr. Penhoet was a co-founder of the Chiron Corporation, a biotechnology company, where he served as President, Chief Executive Officer and a director from its formation in 1981 to April 1998. From 1971 to 1981, Dr. Penhoet was a faculty member of the Biochemistry Department at the University of California, Berkeley. From 2004 until 2008, Dr. Penhoet served as President of the Gordon and Betty Moore Foundation. Dr. Penhoet is a member of the Institute of Medicine of the National Academy of Sciences and The American Academy of Arts & Sciences and currently serves or has during the past five years served as director of Chiron, Corcept Therapeutics, Inc., IDM Pharma, Inc. and Renovis, Inc., together with several privately held buitechnology companies. Dr. Penhoet received a B.A. in Biology from Stanford University and a Ph.D. in Biochemistry from the University of Washington.

^ Return to Top